Conclusion of non-exclusive pharmaceutical discount agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient umeclidinium (ATC code according to WHO: R03BB07)
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Umeclidinium (ATC-Code nach WHO: R03BB07)
Germany
Contract
BuyerAOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
TypeSupplies
Estimated valuevalue not published
Published16 January 2026
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 45 | 2013–2024 |
| Aliud Pharma GmbH · Laichingen | 41 | 2013–2021 |
| ratiopharm GmbH | 37 | 2016–2024 |
| betapharm Arzneimittel GmbH · Augsburg | 35 | 2013–2021 |
| axicorp Pharma B.V. · EC Den Haag | 30 | 2016–2021 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019282
2020224
2021274
2022178
2023247
2024285
2025539
2026219
Who knows the rhythm prepares instead of reacting.
559
days until the deadline — Tuesday 29 February at 21:58
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →